Wednesday, July 25, 2018

IMPRIMIS PHARMACEUTICALS, INC. (NASDAQ:IMMY) Files An 8-K ...

Market Exclusive-16 hours ago
The Company operates through the business of developing drug therapies ... on developing and dispensing a portfolio of non-proprietary compounded drugs for .
Boosting the safety of bulk drug substances is aim of FDA measures

European Pharmaceutical Review · 11 hours ago

Tuesday, July 24, 2018